As the first oral formulation in this drug class, it offers an alternative to injectable GLP-1 agonists whilst maintaining similar efficacy in glycaemic control
Lucky for us this means that new medicines brought to market are virtually guaranteed to be more effective than if they were introduced last century
For instance, both Tesofensine and GLP-1 agonists can lower blood sugar, so adjustments to diabetes medications may be necessary
Wang N, Gao J, Jia M, Ma X, Lei Z, Da F, Yan F, Zhang H, Zhou Y, Li M
Interestingly, when IGF-1 (10 nM) was co-incubated with an equal concentration of scLCDV1-VILP, autophosphorylation of IGF1R Y1135/Y1136 and phosphorylation of AKT S473 and ERK1/ERK2 T202/Y204 were reduced by ~40%
"Urinary and plasma homocysteine and cysteine levels during prolonged oral N-acetylcysteine therapy." Pharmacology